Blog
RSS FeedPosted by Michael Wonder on 28 Mar 2017
Tesaro won’t reveal price of ovarian cancer drug. But it’ll likely be near $14,000 a month.
28 March 2017 - Zejula’s main rivals cost around $13,700 and $12,600 a month, but Tesaro might be able to justify ...
Posted by Michael Wonder on 28 Mar 2017
Severe eczema drug is approved by FDA; price tag is $37,000 a year
28 March 2017 - The FDA on Tuesday approved a drug to treat people with a serious form of eczema, ...
Posted by Michael Wonder on 28 Mar 2017
FDA approves new eczema drug Dupixent
28 March 2017 - The U.S. FDA today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent ...
Posted by Michael Wonder on 28 Mar 2017
NICE says pancreatic cancer drug is not cost effective for routine NHS use
28 March 2017 - NICE says that a drug for metastatic pancreatic cancer is not beneficial enough to justify its high ...
Posted by Michael Wonder on 28 Mar 2017
Xeljanz (tofacitinib citrate) receives marketing authorisation in the European Union for the treatment of moderate to severe active rheumatoid arthritis
27 March 2017 - Approval provides people living with rheumatoid arthritis in the European Union with a new oral treatment option. ...
Posted by Michael Wonder on 28 Mar 2017
FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers
27 March 2017 - The U.S. FDA today approved Zejula (niraparib) for the maintenance treatment of adult patients with recurrent ...
Posted by Michael Wonder on 27 Mar 2017
CADTH recommends Teva's Cinqair
22 March 2017 - Recommendation states price needs to be reduced by 90%. ...
Posted by Michael Wonder on 25 Mar 2017
European Medicines Agency’s CHMP recommends approval of Merck’s Keytruda (pembrolizumab) for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma
24 March 2017 - Recommendation Is for adult patients who have failed autologous stem cell transplant and brentuximab vedotin or ...
Posted by Michael Wonder on 25 Mar 2017
FDA approves Symproic (naldemedine) once daily tablets C-II for the treatment of opioid-induced constipation in adults with chronic non-cancer pain
23 March 2017 - Shionogi and Purdue Pharma announced today that the U.S. FDA approved Symproic (naldemedine) 0.2 mg tablets ...
Posted by Michael Wonder on 24 Mar 2017
Bristol-Myers Squibb receives positive CHMP opinion recommending Opdivo (nivolumab) for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy
24 March 2017 - Positive opinion based on overall survival benefit demonstrated in the Phase 3 CheckMate -141 trial. ...
Posted by Michael Wonder on 24 Mar 2017
European Commission approves Amgevita (biosimilar adalimumab) for the treatment of certain inflammatory diseases
23 March 2017 - First biosimilar adalimumab approved in the European Union. ...
Posted by Michael Wonder on 23 Mar 2017
CADTH recommends reimbursement of Stelara for new indication
21 March 2017 - The cost of treatment with ustekinumab should not exceed the drug plan cost of the least costly ...
Posted by Michael Wonder on 23 Mar 2017
FDA approves first treatment for rare form of skin cancer
23 March 2017 - The U.S. FDA today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric ...
Posted by Michael Wonder on 22 Mar 2017
Post-menopausal women with a family history of breast cancer should be offered anastrozole, says NICE in updated guidance
22 March 2017 - Post-menopausal women with a family history of breast cancer should be offered anastrozole, NICE has said in ...
Posted by Michael Wonder on 21 Mar 2017
FDA approves drug to treat Parkinson’s disease
21 March 2017 - The U.S. FDA today approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease ...